Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer
Status:
Completed
Trial end date:
2009-11-28
Target enrollment:
Participant gender:
Summary
This was a randomized, multi centre, open label, two treatment, two period, two sequence,
single dose, crossover study, with at least 28 days washout between doses, conducted under
fed (normal breakfast) conditions.